伴慢性扁桃体炎的肾病患者扁桃体切除的安全性及疗效

目的探讨肾病患者扁桃体切除的安全性及疗效。方法比较合并慢性扁桃体炎的肾病患者（肾病组：101例）与慢性扁桃体炎的普通人群（对照组：148例）扁桃体切除术术前白蛋白、凝血酶原时间（PT）、活化部分凝血激酶时间（APTT）及纤维蛋白原（Fih）等指标，术后2周并发症，并观察肾病患者扁桃体切除的疗效及其影响因素。结果与对照组相比，肾病组AIB降低、Fib明显升高，PT及APTT差异无显著性。发热及出血发生率差异无显著性。肾病组术后2周内18例（16．67％）出现肾脏激惹现象者，术后4周肾病完全缓解率47．52％，总有效率79．21％。疗效与其临床表现、扁桃体切除时肾病情况及肾功能状态有关。结论扁桃体切除是治疗合并慢性扁桃体炎的肾病措施之一，临床疗效确切，具有可行性。较为安全。

Safety and effect of tonsillectomy in patients with nephropathy accompanied by chronic tonsillitis

[Objective] To evaluate the safety and effect of tonsillectomy in patients with nephropathy accompanied by chronic tonsillitis. [Methods] Plasma albumin(Alb), prothrombin time(PT), activated pactiai thrombopilastin time(APTT) and fibrinogen (Fib) were detected in patients with nephropathy associated with chronic tonsillitis(nephropathy group:101 cases) and in patients with chronic tonsillitis (control group:148 cases). The complications were observed during 2 weeks after tonsillectomy. The effect of tonsillectomy and its influencing factor were observed in nephropathy group. [Results] As compared with control group, plasma Alb was lower, Fib was higher and PT and APTT did not obviously change in nephropathy group. The incidence of moderate fever and bleeding was not significantly different in two groups. 18 of 101 patients in nephropathy group(16.67%) showed obvious deterioration of urinary findings after tonsillectomy. The complete remission rate and total effective rate in 4 weeks after tonsillectomy was 47.52%, 79.21% respectively. The effect of tonsillectomy was associated with clinical manifestation, the condition of renal disease and renal function. [Conclusion] Tonsillectomy is a significantly effective treatment in patients with nephropathy associated with chronic tonsillitis.It is rational and safe.